Cardiol Therapeutics | Finanzwire

Basculer en Français

8295	Companies
114833	Keywords
55274	Articles
62430	Press releases

Home
Companies
Cardiol Therapeutics

BRIEF

published on 10/28/2024 at 15:51, 23 days 19 hours ago

Cardiol Therapeutics Initiates Phase II/III Clinical Trial for Recurrent Pericarditis

Clinical Trial Cardiol Therapeutics CardiolRx Recurrent Pericarditis MAVERIC-2 Trial
PRESS RELEASE

published on 10/28/2024 at 15:46, 23 days 19 hours ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., initiating phase II/III clinical trial for recurrent pericarditis treatment with CardiolRx

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Clinical Trial Pericarditis Treatment
BRIEF

published on 06/14/2024 at 14:57, 5 months 6 days ago

Cardiol Therapeutics Inc Receives Updated 'Buy' Rating from First Berlin Equity Research

BUY Rating Cardiol Therapeutics CardiolRx Recurrent Pericarditis Phase II Study
PRESS RELEASE

published on 06/14/2024 at 14:52, 5 months 6 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases Cardiol Therapeutics Inc's price target to USD8.50 in Buy recommendation after positive results from phase II trial of CardiolRx for recurrent pericarditis treatment

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Phase II Trial CardiolRx
BRIEF

published on 02/27/2024 at 14:16, 8 months 22 days ago

Cardiol Therapeutics Receives FDA Orphan Drug Designation for CardiolRx

FDA Investment Orphan Drug Designation Cardiol Therapeutics Pericarditis
PRESS RELEASE

published on 02/27/2024 at 14:16, 8 months 22 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation on Cardiol Therapeutics Inc. FDA grants Orphan Drug Designation for CardiolRx in pericarditis treatment. Positive phase II study results expected in Q2 2024

FDA Cardiol Therapeutics Inc First Berlin Equity Research Orphan Drug Designation Pericarditis
PRESS RELEASE

published on 01/19/2024 at 12:41, 10 months 1 day ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research has published an update on Cardiol Therapeutics Inc., reaffirming its BUY recommendation and maintaining the price target of USD 3.60. The report highlights the progress in patient recruitment for CardiolRx's two lead indications, acute myocarditis (AM) and recurrent pericarditis (RP), with expectations of significant near-term catalysts for the stock. Analyst Christian Orquera remains optimistic about the company's investment potential. For the full analysis, visit the link provided.

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Patient Recruitment Investment Potential
PRESS RELEASE

published on 08/30/2023 at 15:06, 1 year 2 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE

published on 05/24/2023 at 13:01, 1 year 5 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE

published on 04/11/2023 at 15:26, 1 year 7 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy

Accesswire

Published on 11/21/2024 at 10:03, 52 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 55 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 55 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 20 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 30 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 25 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 50 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 52 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 55 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 55 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 57 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 35 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 10 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 10 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE